In the biopharmaceutical industry, a quiet war is unfolding—one that involves billions of dollars in market value, patent strategies, and regulatory frameworks. The patent dispute between Swiss pharmaceutical giant Roche and American biotech heavyweight Biogen over Tocilizumab has emerged as a focal point in the global competition surrounding biosimilars. This lawsuit not only concerns the commercial interests of the two companies but also reflects the deeper conflict between biologic patent pro

April 17, 2025 -- electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine and wellness company, announced today that new data presented at the 2025 International Brain Injury Association World Congress highlights the effectiveness of gammaCore® non-invasive vagus nerve stimulation (nVNS) in treating concussive symptoms associated with mild traumatic brain injury (mTBI). Dr. Michael Ament of Cherry Creek Neurology presented his study entitled, “Adjunctive Non-Invasive Vagus

April 21, 2025 -- Eascra Biotech announced today that they have been awarded a U.S. National Science Foundation (NSF) Small Business Innovation Research (SBIR) grant for $274,990 to conduct research and development (R&D) to advance drug delivery systems capable of effectively targeting solid tumors. Eascra’s JBNps (Janus base nanoparticles) are an entirely new type of delivery platform that mimics DNA. The platform delivers RNA therapeutics to hard-to-reach treatment sites like joint cartilage

April 23, 2025 -- Bluejay Therapeutics, a clinical-stage biopharmaceutical company dedicated to developing potentially life-changing therapeutics for serious viral and liver diseases, today announced it will present new preclinical data on the characterization of BJT-188, a liver-targeted fatty acid synthase (FASN) inhibitor being investigated for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), at the European Association for the Study of the Liver (EASL) Congress 2025

April 21, 2025 -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company working to develop a new class of drugs based on targeted protein degradation, today announced that new preclinical combination data for ARV-393 will be presented at the American Association for Cancer Research® (AACR) Annual meeting, April 25-30, 2025 in Chicago, Illinois. The poster highlights the potential for ARV-393 to be combined with various standard of care lymphoma treatments. ARV-393 is Arvinas’ in

尊敬的 芽仔-生物医药用户： 我们很高兴地宣布，芽仔-生物医药将全面升级为Eureka LS！这不仅是一次产品迭代，更是产品能力的跨越式突破——从“大模型”进阶为专注生物医药领域的AI Agent平台，通过5大核心Agent为您提供更精准、更高效的垂直化服务。 为什么选择Eureka LS？ “从被动应答到主动赋能” Eureka LS的AI Agents具备场景化任务处理能力，可深度理解生物医药行业需求，主动完成复杂工作流，助您节省50%-90%的时间成本。 🔍 五大AI Agent已就位 1. Pharma Insights Advisor｜生物医药百科问答 · 您的行业“百科全书”：整合大模型与智慧芽核心数据，5分钟内解答药物研发、投融资决策、政策法规等复杂问题。 · 适用场景：快速获取情报、临床用药指导、竞品动态获取。 2. Pharma Document Analyzer｜生物医药文档精读 · 文献专利的“解构专家”：从海量文档中提取技术要点、研究趋势，将3-5天的精读任务压缩至1天。 · 适用场景：专利分析、学术研究、市场竞品报告生成。 3. Markush Claim

In March 2025, the global pharmaceutical sector witnessed a surge of innovation where technology deeply integrates with clinical needs, spanning key areas such as gene therapy, antibiotic breakthroughs, targeted therapies for rare diseases, and vaccine upgrades. From Fitusiran (the world's first RNAi therapy for hemophilia) to Gepotidacin (a novel antibiotic combating drug-resistant strains), from Diazoxide Choline (the first targeted drug for Prader-Willi Syndrome) to the quadrivalent influenza

April 21, 2025 -- Enlivex Therapeutics Ltd. (Nasdaq: ENLV, the “Company”), a clinical-stage macrophage reprogramming immunotherapy company, today announced that the Company completed enrollment of all patients in the Phase II stage of its randomized, controlled, blinded Phase I/II trial of Allocetra™ in patients with moderate to severe knee osteoarthritis. Overall, 133 patients were randomized and treated in the Phase II stage. Oren Hershkovitz, Ph.D, CEO of Enlivex, commented, “We are please

April 21, 2025 -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center.

Neoadjuvant treatment with pepinemab appears to induce abundant, mature lymphoid structures that correlate with durable clinical benefit of immunotherapy in patients with metastatic melanoma. Pepinemab, Semaphorin 4D blocking immunotherapy, also appears to induce the formation of efficient lymphoid structures in “cold” tumors of patients with recurrent and metastatic head and neck cancer. April 21, 2025 -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a diffe